Effects of daunomycin and daunomycin bound to an HPMA copolymer (daunophilin) on the proliferation of mammalian cells cultivated in vitro were compared. One line of non-tumor cells (LEP human cells) and two tumor cell lines (human HeLa cells and C6 rat cells) were used. It was found that both daunomycin and daunophilin had an inhibitory effect on the proliferation of the three cell lines and that the effect was irreversible. Daunophilin had to be used in concentrations by two orders of magnitude higher (> 1 micrograms/ml) than daunomycin (> 0.01 micrograms/ml) to produce comparable effect on cell growth.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Function of formyl peptide receptor 2 in adriamycin resistance of breast cancer.
Exp Biol Med (Maywood)
January 2025
School of Medicine, Yangzhou Polytechnic College, Yangzhou, Jiangsu, China.
FPRL2 has been shown to be associated with a variety of tumours but has not been well studied in breast cancer. In this study, We combine molecular biology techniques with bioinformatics to analyze the role of FPRL2 in breast cancer and adriamycin resistance. By utilizing bioinformatics, we mine TCGA and GEO public databases to assess FPRL2 expression in breast cancer patients and its correlation with patient prognosis.
View Article and Find Full Text PDFCannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway.
Drug Des Devel Ther
January 2025
School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang, 154000, People's Republic of China.
Background: Doxorubicin (DOX) is a chemotherapeutic agent widely used for cancer treatment and has non-negligible cardiotoxicity. Some previous studies have reported that cannabidiol (CBD) has cardioprotective effects. In this study, we evaluated the protective effects of CBD against DOX-induced cardiomyocyte injury, and explored the downstream molecular mechanism.
View Article and Find Full Text PDFIntrapericardial injection of hydrogels with ASC and their secretome to treat dilated cardiomyopathies.
Sci Rep
January 2025
Instituto do Coração (InCor), Faculdade de Medicina, Hospital das Clínicas HCFMUSP, Universidade de São Paulo, São Paulo, Brazil.
Doxorubicin-induced cardiomyopathy (DOX-IC) is a significant and common complication in patients undergoing chemotherapy, leading to cardiac remodeling and reduced heart function. We hypothesized that the intrapericardial injection of hydrogels derived from the cardiac decellularized extracellular matrix (dECM) loaded with adipose tissue-derived stromal cells (ASC) and their secretome dampens or reverses the progression of DOX-IC. DOX-IC was induced in Wistar male rats through ten weekly intra-peritoneal injections of doxorubicin (cumulative dose: 18 mg/kg).
View Article and Find Full Text PDFAMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.
Proc Natl Acad Sci U S A
February 2025
Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, MA 02114.
Anti-Müllerian hormone (AMH) protects the ovarian reserve from chemotherapy, and this effect is most pronounced with Doxorubicin (DOX). However, DOX toxicity and AMH rescue mechanisms in the ovary have remained unclear. Herein, we characterize the consequences of these treatments in ovarian cell types using scRNAseq.
View Article and Find Full Text PDFEmerging Research and Future Directions on Doxorubicin: A Snapshot.
Asian Pac J Cancer Prev
January 2025
All India Institute of Medical Sciences, Department of Biochemistry, Vijaypur, Jammu, India.
Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!